Transforming Neuroscience Through Digital Biomarkers
We exist to improve people’s lives by empowering healthcare professionals and clinical research teams via innovative mobile platforms powered by artificial intelligence
Transforming Neuroscience Through Digital Biomarkers
We exist to improve people’s lives by empowering healthcare professionals and clinical research teams via innovative mobile platforms powered by artificial intelligence
Establishing a new standard in precision Neuroscience
Healios AG is a Medical Device Software Manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies
With novel, validated and patented Digital Biomarkers, we aim at measuring – with unprecedented sensitivity – changes in motor and cognitive functions in patients with neurological disorders
These novel biomarkers will establish a new standard for both pharmacological research and clinical practice
We believe …
We believe …
We believe that patients are asking for change in the way their illnesses are diagnosed and monitored
We believe new, better treatment can be discovered and brought to market much more efficiently through the smart use of ubiquitous mobile technologies
We believe that mobile technologies can seamlessly connect patients with their treatment teams to achieve improved outcomes
Bringing value to both patients and healthcare professionals
Working with patients, caregivers and healthcare professionals we identified various challenges they experience every day.
Our solution improves the whole patient/HCP relationship and creates opportunities for novel insights and a timely change in diagnosis and disease management
A foundation of significant achievements to fulfill our vision
-
2015Collaboration with Jansen Pharma on Schizophrenia
-
2016Collaboration with Roche in Alzheimer’s
-
2017Collaboration with Genentech & Roche in Multiple Sclerosis
-
2018Awarded ‘Seal of Excellence’ by the European leading research program ‘Horizon 2020’
-
2019Collaboration with University Hospital of Basel in Multiple Sclerosis and awarded Swiss Innovation Award
-
2020Collaboration with RC2NB in Multiple Sclerosis
-
2021
Our flagship program:
Multiple Sclerosis
Healios AG and RC2NB, a leading neuroscience research center, have entered into a multi-year development partnership to further develop and validate digital biomarkers in Multiple Sclerosis. Together, we aim to establish a new generation of endpoints for drug research and clinical practice.
“…These digital biomarkers have the potential of a great innovation for MS research and clinical management. The aim is to change the way neurologists monitor and treat MS. Comprehensive and easily obtained monitoring will inform timely and personalised treatment decisions…”
